ORMP — ORAMED PHARMACEUTICALS INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-02 | Hexter Joshua COO & CBO | Option exercise | 50.0K | 3.69 | 184.5K |
| 2026-07-01 | Hexter Joshua COO & CBO | Open-market sale 10b5-1 plan | 137.0K | 4.46 | 611.4K |
| 2026-07-01 | Gabay Avraham Chief Financial Officer | Open-market sale 10b5-1 plan | 73.4K | 4.51 | 330.7K |
| 2026-03-30 | Kidron Miriam Chief Scientific Officer | Shares withheld for tax | 435.1K | 3.31 | 1.4M |
| 2026-03-30 | KIDRON NADAV President and CEO | Shares withheld for tax | 44.8K | 3.31 | 148.3K |
| 2026-03-17 | Kidron Miriam Chief Scientific Officer | Grant or award | 119.6K | 0.00 | 0 |
| 2026-03-17 | KIDRON NADAV President and CEO | Grant or award | 167.0K | 0.00 | 0 |
| 2026-03-17 | Hexter Joshua COO & CBO | Grant or award | 95.9K | 0.00 | 0 |
| 2026-03-17 | Gabay Avraham Chief Financial Officer | Grant or award | 95.9K | 0.00 | 0 |
| 2026-03-12 | KIDRON NADAV President and CEO | Gift | 100.0K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BML Capital Management, LLC | 10.8M | 3.2M |
| Aquamarine Financial (Cayman) Ltd | 7.2M | 2.1M |
| MERCER GLOBAL ADVISORS INC /ADV | 6.5M | 1.9M |
| Gem Investment Advisors, LLC | 5.6M | 1.6M |
| Murchinson Ltd. | 4.5M | 1.3M |
| BOOTHBAY FUND MANAGEMENT, LLC | 2.0M | 600.7K |
| MARSHALL WACE, LLP | 882.7K | 259.6K |
| Rathbones Group PLC | 792.3K | 233.0K |
| DIMENSIONAL FUND ADVISORS LP | 537.7K | 158.2K |
| WELLS FARGO & COMPANY/MN | 535.8K | 157.6K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-10 | 2026-06-30 | on EDGAR ↗ |
| ARS | 2026-08-03 | 2025-12-31 | on EDGAR ↗ |
| DEFA14A | 2026-08-03 | — | on EDGAR ↗ |
| DEF 14A | 2026-08-03 | 2026-09-15 | on EDGAR ↗ |
| SCHEDULE 13D/A | 2026-07-22 | — | on EDGAR ↗ |
| 4 | 2026-07-02 | 2026-07-01 | on EDGAR ↗ |
| 4 | 2026-07-02 | 2026-07-01 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about ORMP
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →